Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

What if we told you that scientists are currently testing a new weight-loss drug that’s similar to Ozempic but sans the scary ...

--BioAge Labs, Inc., a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the launch of ...

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

BioAge disclosed the moves on Tuesday, alongside news that it has filed a provisional US patent application for a new class of apelin receptor agonists developed in-house. The company plans to advance ...

Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space. The Bay Area biotech has entered an option agreement with Chinese ...

BioAge has shown that in preclinical obesity models, APJ agonism can approximately double the weight loss induced by GLP-1 receptor agonists while restoring healthy body composition and improving ...